Listen
AKANTIOR (polihexanide) - Acanthamoeba keratitis in adults and children from 12 years of age
Opinions on drugs -
Posted on
Sep 12 2025
Reason for request
Inclusion on list
Summary of opinion
Unfavourable opinion for reimbursement in the treatment of Acanthamoeba keratitis in adults and children from 12 years of age.
Clinical Benefit
| Insufficient |
The clinical benefit of AKANTIOR 0.8 mg/mL (polihexanide) eye drops, solution in single-dose container is insufficient in the MA indication to justify public funding. |
Clinical Added Value
| Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments
